Inventage Lab announced through a public disclosure that it will acquire the management rights of Curatis, a vaccine development and CDMO company. Inventage Lab plans to invest a total of KRW 25 billion through the acquisition of Curatis’ convertible bonds and participation in a common stock paid-in capital increase, and through this, it plans to become the largest shareholder by holding approximately 40% of Curatis’ shares.
Through the acquisition of Curatis’ management rights, Inventage Lab plans to quickly establish a manufacturing facility dedicated to long-acting injectables within Osong Bioplant and strengthen its competitiveness. In addition, Inventage Lab recently secured its own GMP through a large-scale funding of KRW 53.8 billion. Curatis’ Osong Bioplant has a global-level GMP manufacturing facility and has a global clinical sample manufacturing track record for the mRNA vaccine it is developing.
Through this acquisition, Inventage Lab will be able to apply its self-developed long-acting drug delivery technology, IVL-DrugFluidic®, to Osong Bioplant, which will enable it to conduct clinical development projects with global and domestic pharmaceutical companies more efficiently and stably, and will also be able to respond immediately to mass production at the commercialization stage at the same manufacturing facility. In addition, it is expected to further strengthen its competitiveness in BD and platform technology sales with global and domestic partners.
Inventage Labs is also aiming to strengthen its competitiveness in the lipid nanoparticle (LNP) business sector applied to next-generation mRNA vaccines and therapeutics. Starting in 2023, it is developing HANDYGENE™ GMP, a mass production equipment for LNP manufacturing, and HANDYGENE™ Lab, a research equipment, and is building a gene therapy contract development and manufacturing organization (CDMO) ecosystem.
Through this collaboration with Inventage Lab, Curatis is expecting to secure a new growth engine and increase corporate value in the long term. In particular, it is expected to secure a stable source of revenue and improve financial soundness by serving as the main GMP manufacturing site responsible for clinical sample manufacturing and commercial manufacturing of Inventage Lab’s development items, such as long-acting GLP-1 obesity treatment injections.
Curatis also plans to maximize its competitiveness as a next-generation mRNA therapeutic CDMO by adding Inventage Lab’s LNP manufacturing platform to its existing manufacturing facilities for mRNA vaccine development. Through the technological and business synergies of both companies, it plans to promote global-level CDMO technology sales based on the ‘Gene to GMP’ concept.
Kim Joo-hee, CEO of Inventage Labs, said, “We are delighted to achieve our key business goals of securing a GMP production base for long-acting injectables and strengthening the value chain of our LNP CDMO business through this acquisition. The synergies that will be created between our two companies will be a significant turning point that will further enhance the competitiveness of the Inventage Lab platform in the global market.” He added, “Curatis will be able to secure long-term growth momentum by adding new business items and an advanced platform.”
“This transaction will further strengthen our vaccine development capabilities and CDMO competitiveness by combining Inventage Lab’s capital and technology,” said Kim Sung-jun, CEO of Curatis. “Based on this, we will rapidly grow into a CDMO with global competitiveness to meet market expectations.”
- See more related articles
You must be logged in to post a comment.